Skip to the reading
Sermorelin Then & Now

Why Sermorelin for kids belongs in its own chapter

Looking up a medicine once used for children can send you straight into adult wellness claims. That’s quite a change of subject. Sermorelin’s children’s studies were about a diagnosed hormone shortage and height growth. They deserve a closer look on their own.

A school-age child stands in a sunny bedroom wearing a plain jacket with sleeves ending above the wrists.

1993

Trying a nasal form

The nasal study didn’t speed up growth

A small nasal-treatment study followed eight short children before puberty for six months. Their height growth didn’t speed up. The authors judged that nasal preparation unsuitable for children.

That result belongs to the form they tested. It doesn’t rule on every possible future preparation, and it doesn’t erase findings from injection studies. It does show why the way a medicine enters the body matters. Sharing a name is no guarantee that two forms will produce the same result.

1996

Measuring height

Faster growth was the useful finding

In the 1996 growth study, children with growth hormone deficiency grew faster during treatment. In the group analyzed, average yearly growth went from about 4.1 cm before treatment to 7.2 cm at the twelve-month check. Those numbers describe growth speed, rather than how tall the children eventually became.

There was no untreated comparison group. Families and researchers also knew which treatment the children received. So the finding is useful, but it can’t settle every question about childhood growth. It tells us even less about adult wellness.

1997

The treatment approval

This wasn’t an approval for short stature in general

The 1997 approval covered children with growth failure linked to an unexplained growth hormone shortage. The medical term was “idiopathic growth hormone deficiency.” Being shorter than other children wasn’t, by itself, the approved use.

Think of Sermorelin as a request for growth hormone. The pituitary, the small gland beneath the brain, receives that request and releases the hormone. The review of earlier pediatric use explains that difference and records side effects, including short-lived facial flushing and injection-site pain. An approved role never meant a treatment had no downsides.

What does the old approval mean for a family now?

The old approvals ended in 2009. The FDA later found that the products hadn’t left sale for safety or effectiveness reasons, but that didn’t restore their approvals. Compounded Sermorelin today is not FDA-approved.

For a parent, the useful question starts with the child’s growth pattern and what might explain it. That needs a pediatric specialist’s assessment. An old study can explain what researchers saw; it can’t diagnose a child or choose treatment. The prescription page explains why a current decision needs more than a familiar medicine name.